ArticleHarm reduction journal2023
Safer opioid supply: qualitative program evaluation.
Article in Harm reduction journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Safer opioid supply clients' values and preferences: a systematic review and thematic synthesis of qualitative research.BMJ mental health · 2025Pooled it
- "Anybody who Looks at This Program and Doesn't See the Positive Side from it Doesn't Fully Understand": Participant Perspectives on an Injectable Opioid Agonist Treatment Program in New Brunswick, Canada.Contemporary drug problems · 2026Article
- Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis.Addiction (Abingdon, England) · 2026Article
- Police experiences with cannabis legalization and perceptions of broader drug policy reform.The International journal on drug policy · 2026Article
- "Safer supply is the thing that changes everything": the role of prescribed safer supply in rebuilding trust following experiences of medical abandonment.BMC public health · 2026Article
- Participant perspectives on a safe supply program in Vancouver, Canada: impacts, satisfaction and improvement priorities.Harm reduction journal · 2026Article
- A sea of need: provider accounts of strategies used to manage admission demands to safer opioid supply programs in Ontario.Harm reduction journal · 2025Article
- 'I won't make it without this program': the impact of safer opioid supply program closures in Ontario.Harm reduction journal · 2025Article
- Clinicians' Perspectives and an Ethical Analysis of Safer Supply Opioid Prescribing.Journal of bioethical inquiry · 2025Article
- "Anything can happen": experiences of people using opioids in a xylazine market.Harm reduction journal · 2025Article
- Safer Opioid Supply programs: Hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Opioid medication doses among safer supply clients: Current safer supply doses and previous OAT experience.Drug and alcohol dependence reports · 2025Article
- Comprehensive substance use services within primary care settings: The Safer Opioid Supply program at London InterCommunity Health Centre.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Barriers and facilitators to safer supply pilot program implementation in Canada: a qualitative assessment of service provider perspectives.Harm reduction journal · 2025Article
- Perceived impacts of North Americas first de-medicalized safer supply program.Substance abuse treatment, prevention, and policy · 2025Article
- The public health risks of counterfeit pills.The Lancet. Public health · 2025Article
- "You take care of people, people will take care of you": Moral Economies and an Unpredictable Drug Market.PloS one · 2025Article
- Early experiences and impacts of a fentanyl powder safer supply program in Vancouver, Canada: a qualitative study.The American journal of drug and alcohol abuse · 2025Article
- Perspectives on Diversion of Medications From Safer Opioid Supply Programs.JAMA network open · 2024Article
- A qualitative evaluation of a fentanyl patch safer supply program in Vancouver, Canada.The International journal on drug policy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the overdose crisis in Canada continues to escalate in severity, novel interventions and programs are required. Safer Supply programs offer pharmaceutical-grade medication to people who use drugs to replace and decrease harms related to the toxic illicit drug supply. Given the paucity of research surrounding these programs, we sought to better understand the experience of being part of a Safer Supply program from the perspective of current participants.
methodsWe completed semi-structured interviews and surveys with Safer Supply participants in Ottawa, Canada. Interviews were audio-recorded, transcribed, and analyzed thematically. Descriptive statistics were used to report survey data.
resultsParticipants most commonly discussed Safer Supply benefits. This included programs offering a sense of community, connection, hope for the future, and increased autonomy. Participants also described program concerns, such as restrictive protocols, inadequate drugs, and diversion.
conclusionsOur research demonstrated that participants found Safer Supply to be effective and impactful for their substance use goals. While participants did discuss concerns about the program, overall, we found that this is an important harm reduction-based program for people who use drugs in the midst of the overdose crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.